Sign In
Buy BNTX
$90.58
-2.27 (-2.44%)
At Close: Jul 31, 2026
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut
01:49pm, Thursday, 18'th Sep 2025
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.
Why BioNTech Stock Sank by More Than 7% Today
06:19pm, Friday, 12'th Sep 2025
A star stock during the pandemic era wasn't shining so brightly on Friday. On a media report that the current presidential administration is preparing to link a set of fatalities to Covid vaccines, Bi
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
01:37pm, Friday, 12'th Sep 2025
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
10:11am, Friday, 12'th Sep 2025
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
02:01pm, Monday, 08'th Sep 2025
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
11:05am, Monday, 08'th Sep 2025
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G
MAINZ, Germany, and PRINCETON, USA, September 8, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today presented interim data from a global
Pfizer, partner BioNTech say updated COVID shot shows better immune response
07:02am, Monday, 08'th Sep 2025
Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlyi
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinic
Why BioNTech Stock Crushed the Market Today
04:41pm, Friday, 05'th Sep 2025
BioNTech (BNTX 8.62%), the Germany-based biotech that scored big early in the pandemic era with the Comirnaty vaccine it developed with Pfizer, had some fresh news from the lab to report on Friday. In
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
09:23am, Friday, 05'th Sep 2025
BioNTech stock surged Friday after its experimental breast cancer treatment met a pre-specified bar for success in a pivotal study.
BioNTech, Duality score initial trial win with breast cancer precision drug
05:13am, Friday, 05'th Sep 2025
BioNTech and its partner Duality Biologics said on Friday that a late-stage trial testing their precision drug against a certain type of breast cancer reached its main goal of slowing down disease pro
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has ap
CureVac settles patent dispute litigation with Pfizer and BioNTech
09:00pm, Thursday, 07'th Aug 2025
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
